Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · IEX Real-Time Price · USD
3.690
-0.010 (-0.27%)
Jul 22, 2024, 10:10 AM EDT - Market open
Alzamend Neuro Employees
As of April 30, 2023, Alzamend Neuro had 7 total employees, including 4 full-time and 3 part-time employees. The number of employees decreased by 1 or -12.50% compared to the previous year.
Employees
7
Change (1Y)
-1
Growth (1Y)
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,771,678
Market Cap
2.95M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Aditxt | 47 |
TC Biopharm (Holdings) | 41 |
ASLAN Pharmaceuticals | 35 |
Healthcare Triangle | 31 |
INVO Bioscience | 30 |
Petros Pharmaceuticals | 21 |
Virax Biolabs Group | 11 |
CNS Pharmaceuticals | 5 |
ALZN News
- 2 months ago - Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program - Business Wire
- 8 months ago - Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement - Business Wire
- 1 year ago - Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's - Business Wire
- 1 year ago - Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type - Business Wire
- 1 year ago - BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock - Business Wire
- 1 year ago - In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc. - Accesswire
- 1 year ago - BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period - Business Wire
- 1 year ago - BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease - Business Wire